Akero Therapeutics Inc (AKRO)
19.64
-1.16
(-5.55%)
USD |
NASDAQ |
May 10, 16:00
19.64
0.00 (0.00%)
After-Hours: 20:00
Akero Therapeutics Enterprise Value: 909.06M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 909.06M |
| May 08, 2024 | 924.23M |
| May 07, 2024 | 993.18M |
| May 06, 2024 | 999.38M |
| May 03, 2024 | 830.46M |
| May 02, 2024 | 833.91M |
| May 01, 2024 | 859.42M |
| April 30, 2024 | 846.32M |
| April 29, 2024 | 827.70M |
| April 26, 2024 | 835.98M |
| April 25, 2024 | 780.13M |
| April 24, 2024 | 871.83M |
| April 23, 2024 | 922.85M |
| April 22, 2024 | 908.37M |
| April 19, 2024 | 906.30M |
| April 18, 2024 | 889.07M |
| April 17, 2024 | 964.22M |
| April 16, 2024 | 977.32M |
| April 15, 2024 | 972.49M |
| April 12, 2024 | 1.004B |
| April 11, 2024 | 980.77M |
| April 10, 2024 | 984.90M |
| April 09, 2024 | 1.112B |
| April 08, 2024 | 1.070B |
| April 05, 2024 | 1.076B |
| Date | Value |
|---|---|
| April 04, 2024 | 1.059B |
| April 03, 2024 | 1.073B |
| April 02, 2024 | 1.087B |
| April 01, 2024 | 1.135B |
| March 28, 2024 | 1.217B |
| March 27, 2024 | 1.161B |
| March 26, 2024 | 1.157B |
| March 25, 2024 | 1.141B |
| March 22, 2024 | 1.208B |
| March 21, 2024 | 1.263B |
| March 20, 2024 | 1.212B |
| March 19, 2024 | 1.257B |
| March 18, 2024 | 1.326B |
| March 15, 2024 | 1.374B |
| March 14, 2024 | 1.362B |
| March 13, 2024 | 1.403B |
| March 12, 2024 | 1.437B |
| March 11, 2024 | 1.496B |
| March 08, 2024 | 1.625B |
| March 07, 2024 | 1.213B |
| March 06, 2024 | 1.164B |
| March 05, 2024 | 1.193B |
| March 04, 2024 | 1.224B |
| March 01, 2024 | 1.041B |
| February 29, 2024 | 994.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
103.76M
Minimum
Oct 27 2023
2.828B
Maximum
Jun 13 2023
855.54M
Average
641.47M
Median
Aug 23 2019
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.472B |
| 89bio Inc | 313.90M |
| Viking Therapeutics Inc | 7.882B |
| Eli Lilly and Co | 757.00B |
| Ionis Pharmaceuticals Inc | 4.830B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.19M |
| Total Expenses (Quarterly) | 61.87M |
| EPS Diluted (Quarterly) | -1.02 |
| Earnings Yield | -14.66% |